The purpose of this study is to make boceprevir, an experimental drug, available to subjects infected with hepatitis C virus genotype 1 who failed to achieve sustained virologic response (SVR) after treatment in a previous study of boceprevir combination therapy. Boceprevir is a protease inhibitor that interferes with the ability of tthe hepatitis C virus to release new active virus into the blood stream. This study will look at the safety of boceprevir taken with Pegintron and ribavirin in subjects who failed to achieve SVR after completing their per-protocol defined regimen.